| Psoriasis vulgaris
Cosentyx vs Tazorac
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Cosentyx vs Tazorac with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazorac has a higher rate of injection site reactions vs Cosentyx based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazorac but not Cosentyx, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cosentyx
Tazorac
At A Glance
SC injection
Every 4 weeks
IL-17A antagonist
Topical
Daily
Retinoid
Indications
- Psoriasis vulgaris
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Enthesitis-Related Arthritis
- Hidradenitis Suppurativa
- Psoriasis vulgaris
- Acne Vulgaris
Dosing
Psoriasis vulgaris 300 mg SC at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; 150 mg may be acceptable for some adults; pediatric patients 6 years and older receive weight-based dosing on the same schedule.
Arthritis, Psoriatic 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to 300 mg SC every 4 weeks if active disease persists; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Ankylosing spondylitis 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to 300 mg SC every 4 weeks if active disease persists; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Non-Radiographic Axial Spondyloarthritis 150 mg SC with or without a loading dose at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; IV option: 6 mg/kg loading at Week 0, then 1.75 mg/kg every 4 weeks infused over 30 minutes.
Enthesitis-Related Arthritis Weight-based SC dosing for pediatric patients 4 years and older at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; 150 mg for patients >= 50 kg.
Hidradenitis Suppurativa 300 mg SC at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; may increase to every 2 weeks in adults with inadequate response; pediatric patients 12 years and older receive weight-based dosing every 4 weeks.
Psoriasis vulgaris Apply a thin film (2 mg/cm2) of 0.05% cream once daily in the evening to psoriatic lesions only; increase to 0.1% if tolerated and medically indicated.
Acne Vulgaris Apply a thin layer (2 mg/cm2) of 0.1% cream once daily in the evening to affected facial skin areas after gentle cleansing and drying.
Contraindications
- Previous serious hypersensitivity reaction to secukinumab or any excipient in COSENTYX
- Pregnancy (retinoids may cause fetal harm)
- Known hypersensitivity to any component of TAZORAC Cream
Adverse Reactions
Most common (>=1%) nasopharyngitis, diarrhea, upper respiratory tract infection, rhinitis, oral herpes, pharyngitis, urticaria, rhinorrhea
Serious infections (including serious infections and sepsis), inflammatory bowel disease (Crohn's disease and ulcerative colitis), neutropenia, anaphylaxis, angioedema
Postmarketing anaphylaxis, angioedema, systemic vasculitis, eczematous eruptions, cutaneous vasculitis, pyoderma gangrenosum, opportunistic infections including esophageal candidiasis, cytomegalovirus gastroenteritis/colitis, Pneumocystis jiroveci pneumonia, hepatitis B virus reactivation, histoplasmosis, toxoplasmosis
Most common (>=10%) Psoriasis: pruritus, erythema, burning; Acne: desquamation, dry skin, erythema, burning sensation
Serious Embryofetal toxicity, photosensitivity and risk of sunburn
Postmarketing Blister, dermatitis, urticaria, skin exfoliation, skin discoloration (hyperpigmentation or hypopigmentation), swelling at or near application sites, pain
Pharmacology
Secukinumab is a human IgG1 monoclonal antibody that selectively binds to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor, suppressing the release of proinflammatory cytokines and chemokines involved in inflammatory and immune responses.
Tazarotene is a retinoid prodrug converted by esterase hydrolysis to tazarotenic acid, which binds retinoic acid receptors RAR-beta and RAR-gamma with relative selectivity and may modify gene expression in psoriatic and acne-affected skin.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cosentyx
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
No coverage data available for Tazorac.
UnitedHealthcare
Cosentyx
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (1/8) · Qty limit (4/8)
No coverage data available for Tazorac.
Humana
Cosentyx
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
No coverage data available for Tazorac.
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Ankylosing Spondylitis: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
No savings programs available for Tazorac.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CosentyxView full Cosentyx profile
TazoracView full Tazorac profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.